Literature DB >> 1404618

Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active.

M Kotler1, G Arad, S H Hughes.   

Abstract

We have introduced mutations into the region of the genome of human immunodeficiency virus type 1 (HIV-1) that encodes the cleavage sites between the viral protease (PR) and the adjacent upstream region of the polyprotein precursor. Segments containing these mutations were introduced into plasmids, and the retroviral proteins were expressed in Escherichia coli. The mutations prevented cleavage between the PR and the adjacent polypeptide; however, other PR cleavage sites in the polyprotein were cleaved normally, showing that the release of free PR is not a prerequisite for the appropriate processing of HIV-1 precursors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404618      PMCID: PMC240177     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

Review 1.  Retroviral proteinases.

Authors:  S Oroszlan; R B Luftig
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.

Authors:  A H Kaplan; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

3.  Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.

Authors:  J M Louis; R A McDonald; N T Nashed; E M Wondrak; D M Jerina; S Oroszlan; P T Mora
Journal:  Eur J Biochem       Date:  1991-07-15

4.  Use of T7 RNA polymerase to direct expression of cloned genes.

Authors:  F W Studier; A H Rosenberg; J J Dunn; J W Dubendorff
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

5.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease.

Authors:  R A Kramer; M D Schaber; A M Skalka; K Ganguly; F Wong-Staal; E P Reddy
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

6.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

7.  The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers.

Authors:  J Vieira; J Messing
Journal:  Gene       Date:  1982-10       Impact factor: 3.688

8.  Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates.

Authors:  M Kotler; W Danho; R A Katz; J Leis; A M Skalka
Journal:  J Biol Chem       Date:  1989-02-25       Impact factor: 5.157

9.  Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity.

Authors:  I Katoh; Y Yoshinaka; A Rein; M Shibuya; T Odaka; S Oroszlan
Journal:  Virology       Date:  1985-09       Impact factor: 3.616

10.  Isolation and characterization of a novel protein (X-ORF product) from SIV and HIV-2.

Authors:  L E Henderson; R C Sowder; T D Copeland; R E Benveniste; S Oroszlan
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

View more
  9 in total

1.  Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

Authors:  D Xie; S Gulnik; E Gustchina; B Yu; W Shao; W Qoronfleh; A Nathan; J W Erickson
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

2.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.

Authors:  Michael E Abram; Michael A Parniak
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain.

Authors:  G Zybarth; H G Kräusslich; K Partin; C Carter
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

5.  Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity.

Authors:  U Tessmer; H G Kräusslich
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria.

Authors:  J Luban; C Lee; S P Goff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.

Authors:  Nathalie Dautin; Gouzel Karimova; Daniel Ladant
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  A p6Pol-protease fusion protein is present in mature particles of human immunodeficiency virus type 1.

Authors:  N Almog; R Roller; G Arad; L Passi-Even; M A Wainberg; M Kotler
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation.

Authors:  Christine Ludwig; Andreas Leiherer; Ralf Wagner
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.